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OBSERVATIONS
Diabetic
Ketoacidosis
Complicated With
Previously Unknown
Gitelman Syndrome
in a Tunisian Child
G
itelman syndrome (GS) is an auto-
somalrecessivediseasecharacterized
byhypokalemia, hypomagnesemia,
metabolic alkalosis, and hypocalciuria
(1). In the great majority of cases, GS is
caused bymutationsinthe SLC12A3gene
encoding the thiazide-sensitive NaCl co-
transporter (NCCT), which is speciﬁcally
expressed in the apical membrane of cells
along the distal convoluted tubule (2).
A 10-year-old Tunisian male patient
was admitted with polyuria, polydipsia,
and profound fatigue associated with
weight loss. His parents were ﬁrst cousins.
Physical examination revealed clouded
sensorium, severe dehydration, fruity-like
breathodor,andKussmaulbreathing.The
laboratory proﬁle revealed hyperglycemia
21.7 mmol/L with ketonuria, acidosis,
serum bicarbonate 6.4 mmol/L, sodium
133 mEql/L, potassium 1.1 mEq/L, and
HbA1c 13.2%. On the basis of Interna-
tional Society for Pediatric and Adoles-
cent Diabetes guidelines, a diagnosis of
diabetic ketoacidosis (DKA) was pro-
posed (3). No abnormalities were showed
by electrocardiogram. Clinical manage-
ment included restoration of intravascular
volume, intravenous insulin, and potas-
sium chloride infusion. After a month
the clinical picture was improved, but
low serum potassium values and low
blood pressure were conﬁrmed. Further
investigations revealed hypocalciuria,
hypochloremic alkalosis, and increased
excretion of potassium. GS was then sus-
pected as the etiology of the hypokalemia.
A homozygous splice site mutation in the
SLC12A3 gene was found with the se-
quence analysis of the NCCT gene. This
mutation was a homozygous G to A base
pair substitution in intron 8 (c.10951
1G.A) leading to the inclusion of 95
amino acids before a stop signal at the
96th codon. Parents were heterozygous
for c.109511G.A. The diagnosis of GS
was thus genetically conﬁrmed.
The association of GS and type 1
diabetes is rare, and it has been described
in one pediatric patient only (4). In the
case described by Zangeneh et al. (4),
the diagnosisof GS had been proposed be-
fore the onset of diabetes. In our case, the
manifestation of diabetes occurred ﬁrst,
and it allowed us to identify the presence
of GS, which was unknown at that time.
DKA is characterized by hyperglyce-
mia, ketonemia, and metabolic acidosis.
The diagnosis of DKA can be confounded
by the coexistence of combined acid-base
disorders. The presence of a congenital
tubulopathy as GS with metabolic alka-
losis can conceal the severe acute DKA on
the initial presentation. Furthermore,
DKA is characterized by hypokalemia
as a result of a signiﬁcant depletion of
renal solutes. The subsequent adminis-
tration of insulin (3) worsened the hy-
pokalemia. As described above, GS is
characterized by hypokalemia and this,
in association with DKA, can make clinical
treatment very difﬁcult. In our case, the
management of ketoacidosis required
highdosesofintravenouspotassiumchlo-
ride to obtain normal potassium se-
rum values. This case presentation shows
that the concomitant presence of GS can
make the diagnosis and the management
of DKA difﬁcult. On the other hand, the
tendencytohavelowerbloodpressureina
patient with GS is a protective factor for
people with diabetes, exposing them to
lower risk of cardiovascular complications.
In a patient with type 1 diabetes onset and
DKA, when the hypokalemia is not fully
normalized with traditional therapy, it is
important to consider the diagnosis of as-
sociated tubulopathies such as GS.
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